Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 7, 2015

GAITHERSBURG, Md., April 30, 2015 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, today announced it will report its first quarter 2015 financial and operating results after the close of U.S. financial markets on Thursday, May 7, 2015.

In addition, management will host a conference call to discuss the quarterly results and provide an update on corporate activities.

Conference call details are as follows:
Date: May 7, 2015
Time: 4:30 pm US Eastern Time
Dial-in number:(877) 212-6076 (Domestic) or (707) 287-9331 (International)
Via web:  www.novavax.com,
 "Investor Info"/"Events" 
  
Conference call replay:
Dates: Starting at 7:30 pm ET on May 7, 2015 until midnight May 14, 2015
Dial-in number: (855) 859-2056 (Domestic) or (404) 537-3406 (International)
Passcode: 35660022
Via web:  www.novavax.com,
 "Investor Info"/"Events"

 
About Novavax

Novavax, Inc. (Nasdaq:NVAX) is a clinical-stage vaccine company committed to delivering novel products to prevent a broad range of infectious diseases. Its recombinant nanoparticles and Matrix-M(TM) adjuvant technology are the foundation for ground-breaking innovation that improves global health through safe and effective vaccines. Additional information about Novavax is available on the company's website,
www.novavax.com
.

   CONTACT: Novavax, Inc.
   Barclay A. Phillips
   SVP, Chief Financial Officer and Treasurer
   Andrea N. Flynn, Ph.D.
   Senior Manager, Investor Relations
   ir@novavax.com
   240-268-2000
   Russo Partners, LLC
   David Schull
   Todd Davenport, Ph.D.
   david.schull@russopartnersllc.com
   todd.davenport@russopartnersllc.com
   212-845-4271
  



This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novavax, Inc. via GlobeNewswire

HUG#1917366